ATE395058T1 - Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten - Google Patents
Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonistenInfo
- Publication number
- ATE395058T1 ATE395058T1 AT00912807T AT00912807T ATE395058T1 AT E395058 T1 ATE395058 T1 AT E395058T1 AT 00912807 T AT00912807 T AT 00912807T AT 00912807 T AT00912807 T AT 00912807T AT E395058 T1 ATE395058 T1 AT E395058T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- treatment
- formula
- prostanoid
- headache
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 206010019233 Headaches Diseases 0.000 title 1
- 102000011367 Prostanoid EP4 receptors Human genes 0.000 title 1
- 108050001693 Prostanoid EP4 receptors Proteins 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 231100000869 headache Toxicity 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000018238 Primary Headache disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000003851 azoles Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2000/001138 WO2001072302A1 (en) | 2000-03-24 | 2000-03-24 | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE395058T1 true ATE395058T1 (de) | 2008-05-15 |
Family
ID=9883925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00912807T ATE395058T1 (de) | 2000-03-24 | 2000-03-24 | Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267867B1 (de) |
| JP (1) | JP2003528144A (de) |
| AT (1) | ATE395058T1 (de) |
| AU (2) | AU2000234451B2 (de) |
| CA (1) | CA2402099C (de) |
| DE (1) | DE60038902D1 (de) |
| DK (1) | DK1267867T3 (de) |
| WO (1) | WO2001072302A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1450813B1 (de) * | 2001-10-31 | 2007-08-29 | Medical Research Council | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| WO2008104055A1 (en) * | 2007-02-26 | 2008-09-04 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| LT3625224T (lt) | 2017-05-18 | 2021-10-25 | Idorsia Pharmaceuticals Ltd | N-pakeistieji indolo dariniai |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
| PT3625228T (pt) | 2017-05-18 | 2021-09-16 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores dos recetores de pge2 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100345943B1 (ko) * | 1993-12-20 | 2002-11-30 | 후지사와 야꾸힝 고교 가부시키가이샤 | 4,5-디아릴옥사졸유도체 |
| AUPO713297A0 (en) * | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
| GB9720270D0 (en) * | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| JP2003506404A (ja) * | 1999-08-10 | 2003-02-18 | グラクソ グループ リミテッド | 治療、とりわけ神経障害性疼痛および結腸癌の治療におけるｅｐ４受容体リガンドの使用 |
-
2000
- 2000-03-24 JP JP2001570263A patent/JP2003528144A/ja active Pending
- 2000-03-24 DK DK00912807T patent/DK1267867T3/da active
- 2000-03-24 WO PCT/GB2000/001138 patent/WO2001072302A1/en not_active Ceased
- 2000-03-24 AU AU2000234451A patent/AU2000234451B2/en not_active Ceased
- 2000-03-24 AT AT00912807T patent/ATE395058T1/de not_active IP Right Cessation
- 2000-03-24 DE DE60038902T patent/DE60038902D1/de not_active Expired - Lifetime
- 2000-03-24 CA CA2402099A patent/CA2402099C/en not_active Expired - Fee Related
- 2000-03-24 AU AU3445100A patent/AU3445100A/xx active Pending
- 2000-03-24 EP EP00912807A patent/EP1267867B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2000234451B2 (en) | 2005-09-29 |
| EP1267867A1 (de) | 2003-01-02 |
| WO2001072302A1 (en) | 2001-10-04 |
| EP1267867B1 (de) | 2008-05-14 |
| DE60038902D1 (de) | 2008-06-26 |
| DK1267867T3 (da) | 2008-08-25 |
| CA2402099A1 (en) | 2001-10-04 |
| AU3445100A (en) | 2001-10-08 |
| CA2402099C (en) | 2011-04-26 |
| JP2003528144A (ja) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69400824D1 (de) | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne | |
| ATE469892T1 (de) | Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung | |
| DE60217147D1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
| DE69415614D1 (de) | N-acylierte trizyklische Azaheteroringe verwendbar als Vasopressin-Antagonisten | |
| DE60222396D1 (de) | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste | |
| DE60038902D1 (de) | Verwendung von prostanoid-ep4-rezeptor-antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| MXPA02003792A (es) | Moduladores de molecula pequena de receptores de serotonina endogenos constitutivamente activados. | |
| MXPA03010586A (es) | N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3. | |
| EA200200731A1 (ru) | Производные фенилпиперазинила | |
| EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| EA200600860A1 (ru) | Производные n-тиазол-2-илбензамида | |
| EA200000910A1 (ru) | Азабициклические лиганды рецепторов 5нт1 | |
| ATE304522T1 (de) | Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten | |
| EA200500830A1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| DE69821142D1 (de) | Verwendung von prostanoiden-antagonisten zur bhandlung von primären kopfschmerzen | |
| DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| DE60206762D1 (de) | Hexahydroazepino[4,5-g]indole und -indoline als 5-ht-rezeptor-liganden | |
| BR9916618A (pt) | Compostos heterocìclicos antidepressivos | |
| ATE254122T1 (de) | Indolderivate als 5-ht1b und 5-ht1d agonisten | |
| ATE441642T1 (de) | Hydantoin derivate mit affinität für somatostatin rezeptoren | |
| ATE119532T1 (de) | 7-oxabicycloheptyl-substituierte, heterocyclische amid-prostaglandin-analoge, verwendbar bei der behandlung von vasospastischen und thrombotischen krankheiten. | |
| GB0103045D0 (en) | Organic Compounds | |
| ATE260918T1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |